Equity · Healthcare
IMVT
NASDAQImmunovant (IMVT)
The line runs 40.91 USD on 11 August through 37.35 USD on 11 September, on a scale from 35 to 50. Days the market did not trade hold the previous close, flat.
- Market cap
- 7.7B USD
- EPS, diluted, year to Mar 2026
- −2.77 USD
- 52-week range
- 15 USD – 45 USD
- Avg volume
- 105.9K
as of Sep 11, 2026
Have Immunovant (IMVT) insiders bought or sold shares recently?
In the 90 days to 9 Nov 2026, Immunovant insiders reported 9 open-market sales and no purchases (SEC Form 4); none has bought on the open market since 12 Dec 2025.
Form 4, 90 days to 9 Nov 2026, newest reported trade 28 Oct 2026
Buys 0Sells 9Net sold $923KOther filings 3
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 28 Oct 2026 | Girao TiagoChief Financial Officer | Sell | 6,606 | 188K USD |
| 21 Oct 2026 | Stout Jay SChief Technology Officer | Sell | 2,595 | 75K USD |
| 07 Oct 2026 | Gloria MelanieChief Operating Officer | Sell | 2,241 | 72K USD |
| 07 Oct 2026 | Stout Jay SChief Technology Officer | Sell | 3,809 | 122K USD |
| 07 Oct 2026 | Van Tuyl ChristopherChief Legal Officer | Sell | 1,327 | 43K USD |
| 02 Oct 2026 | Venker EricChief Executive Officer | Sell | 3,506 | 120K USD |
| 23 Sep 2026 | Van Tuyl ChristopherChief Legal Officer | Sell | 2,846 | 103K USD |
| 28 Aug 2026 | Pande AtulDirector | Sell | 1,500 | 65K USD |
| 20 Aug 2026 | Gloria MelanieChief Operating Officer | Sell | 3,056 | 135K USD |
| Sold | 9 open-market sales | 27,486 | $923K |
3 other filings in the window: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 01 Oct 2026 | Venker EricChief Executive Officer | Option exercise | 92,187 | 1.3M USD |
| 01 Oct 2026 | Venker EricChief Executive Officer | Other | 85,886 | 2.9M USD |
| 28 Aug 2026 | Pande AtulDirector | Option exercise | 1,500 | 13K USD |
Which funds hold Immunovant (IMVT)?
1 of the 45 institutional funds we track reported a Immunovant position for the quarter ended 30 Sep 2026 — a combined 18.4M USD; the latest of those filings landed 06 Nov 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Fisher Asset Management | New position | 545,730 | 18.4M USD |
What has been filed or recorded for Immunovant (IMVT)?
The filings we hold for Immunovant, newest first: 1 fails-to-deliver day, 6 quarterly earnings reports, 2 annual reports and 4 reported financial figures, the latest dated 07 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 07 Oct 2026 | Fails to deliver | Shares failed to deliver | 38 shares | 1K USD notional · <0.001% of shares out |
| 30 Jun 2026 | Quarterly earnings | Q1 2027 reported | EPS −0.75 USD | |
| 30 Jun 2026 | Financials | Total assets | 852.5M USD | at period end |
| 30 Jun 2026 | Financials | Total equity | 735.4M USD | at period end |
| 31 Mar 2026 | Annual report | FY 2026 reported | EPS −2.77 USD | |
| 31 Mar 2026 | Financials | Net income | −505.6M USD | fiscal year |
| 31 Mar 2026 | Financials | Diluted EPS | −2.77 USD | fiscal year |
| 31 Dec 2025 | Quarterly earnings | Q3 2026 reported | EPS −0.61 USD | |
| 30 Sep 2025 | Quarterly earnings | Q2 2026 reported | EPS −0.73 USD | |
| 30 Jun 2025 | Quarterly earnings | Q1 2026 reported | EPS −0.71 USD | |
| 31 Mar 2025 | Annual report | FY 2025 reported | EPS −2.73 USD | |
| 31 Dec 2024 | Quarterly earnings | Q3 2025 reported | EPS −0.76 USD | |
| 30 Sep 2024 | Quarterly earnings | Q2 2025 reported | EPS −0.74 USD |
Immunovant (IMVT): frequently asked questions
What did Immunovant shares close at?
Immunovant closed at 37.35 USD on 11 Sep 2026, down 1.71% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Immunovant’s market cap?
Immunovant is worth 7.7B USD by market value as of 11 Sep 2026, which is the share price times the shares on issue from its SEC filings.
Have Immunovant insiders bought or sold shares recently?
In the 90 days to 9 Nov 2026, Immunovant insiders reported 9 open-market sales and no purchases (SEC Form 4); none has bought on the open market since 12 Dec 2025. A further 3 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders
Which funds own Immunovant?
1 of the 45 funds we track reported a Immunovant position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported position was Fisher Asset Management. See Funds
When did Immunovant last report earnings?
Immunovant last reported earnings on 30 Jun 2026 for Q1 2027, with EPS of −0.75 USD; no next date is announced in SEC filings yet. See Filings
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), most closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Jun 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings